Altimmune (ALT) Non Operating Investment Income (2010 - 2012)
Altimmune (ALT) reported Non Operating Investment Income of $823809.0 for Q2 2012, up 19.7% year-over-year from $688221.0 in Q3 2011, and up 183.07% on a QoQ basis from -$991662.0 in Q1 2012.
Altimmune (ALT) has 3 years of Non Operating Investment Income data on file, last reported at $823809.0 in Q2 2012.
- Quarterly Non Operating Investment Income rose 19.7% year-over-year to $823809.0 in Q2 2012, while the trailing twelve-month figure through Jun 2012 was $3.8 million (up 247.2% YoY) and the FY2011 annual result came in at $7.1 million, up 230.92% from the prior year.
- Non Operating Investment Income rose to $823809.0 in Q2 2012 per ALT's latest filing, from -$991662.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $2.9 million in Q3 2011 and bottomed at -$5.8 million in Q4 2010.
- The 3-year median for Non Operating Investment Income is $688221.0 (2011), against an average of $139120.4.
- The widest annual swing landed in 2011, when Non Operating Investment Income soared 3734.79%; it then slumped 139.85% in 2012.
- Tracing ALT's Non Operating Investment Income over 3 years: stood at -$5.8 million in 2010, then surged by 118.33% to $1.1 million in 2011, then slipped by 22.97% to $823809.0 in 2012.
- Per Business Quant, the three latest ALT Non Operating Investment Income figures stand at $823809.0 (Q2 2012), -$991662.0 (Q1 2012), and $1.1 million (Q4 2011).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2012 | 823,809.00 |
| Jun 30, 2012 | 823,809.00 |
| Mar 31, 2012 | -991,662.00 |
| Mar 31, 2012 | -991,662.00 |
| Dec 31, 2011 | 1.07 Mn |
| Dec 31, 2011 | 1.07 Mn |
| Sep 30, 2011 | 2.90 Mn |
| Sep 30, 2011 | 2.90 Mn |
| Jun 30, 2011 | 688,221.00 |
| Jun 30, 2011 | 688,221.00 |
| Mar 31, 2011 | 2.49 Mn |
| Mar 31, 2011 | 2.49 Mn |
| Dec 31, 2010 | -5.83 Mn |
| Dec 31, 2010 | -5.83 Mn |
| Sep 30, 2010 | 75,594.00 |
| Sep 30, 2010 | 75,594.00 |
| Jun 30, 2010 | 33,470.00 |
| Jun 30, 2010 | 33,470.00 |